A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Phase 2 Unknown 36 enrolled Theratocular Biotek Co.

RandomizedParallel-groupSingle-blindTreatment

Summary

A 2 parts Phase II study to investigate the effect on central macular thickness of treatment with MG-O-1002 eye drops in participants aged over 45 with neovascular age-related macular degeneration (nAMD)

Timeline

Start: 2022-08-09
Primary completion: 2024-03
Completion: 2024-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MG-O-1002	Unknown	0.8 %	Topical

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Summary

Timeline

Drugs

Indications